---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-062025"
form_type: "8-K"
ticker: null
cik: "0001309057"
company_name: "China Health Industries Holdings, Inc."
filed_at: "2024-07-17T23:59:59+00:00"
generated_at: "2026-05-31T20:09:45.072357+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "medium"
source: SEC EDGAR
---

# China Health sells subsidiary to Chairman Xin Sun for 594k shares and $6k cash

## Summary
- On July 11, 2024, China Health closed the sale of 100% of Harbin Humankind Biology Technology to Chairman/CEO Xin Sun (99%) and his sister Liyuan Sun (1%).
- Consideration: $594,000 paid via transfer of 594,000 shares of CHHE common stock (valued at $1.00/share) from Xin Sun; $6,000 cash from Liyuan Sun.
- The subsidiary Humankind was previously wholly owned by China Health HK; its assets were transferred to another subsidiary (Hankang) prior to the sale.
- This is a related-party transaction; no valuation or financial details of Humankind provided.

## SEC filing metadata
- accession: 0001213900-24-062025
- form_type: 8-K
- cik: 0001309057
- company_name: China Health Industries Holdings, Inc.
- filed_at: 2024-07-17T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: medium
- sec_items: 1.01, 2.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1309057/000121390024062025/0001213900-24-062025-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1309057/000121390024062025/ea0209557-8k_china.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-062025
- JSON: https://secwatch.observer/filing/0001213900-24-062025.json
- Plain text: https://secwatch.observer/filing/0001213900-24-062025.txt

## Key facts
- M&A Transactions
  China Health Industries Holdings, Inc. completed a disposition involving Mr. Xin Sun and Ms. Liyuan Sun for USD 600,000.
  - Action: disposition
  - Counterparty: Mr. Xin Sun and Ms. Liyuan Sun
  - Consideration: USD 600,000
  source text: China Health HK agreed to transfer to Mr. Xin Sun 99% and Ms. Liyuan Sun 1% of the equity interests of Harbin Humankind Biology Technology Co., Limited. (“Humankind”), for a consideration of USD 594,000 and USD 6,000 respectively, totaling USD 600,000
  evidence_url: https://www.sec.gov/Archives/edgar/data/1309057/000121390024062025/0001213900-24-062025-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.